Table 1.
General characteristics of the study patients with HCV infection
| Characteristic | Entire cohort (n = 36) |
| Female, n (%) | 24 (66.6%) |
| Age (yr) | 47.9 ± 13.2 |
| Estimated duration of HCV infection (mo) | 58 (24-120) |
| HCV RNA (IU/mL) | 2471075 ± 2490186 |
| Body mass index (kg/m2) | 28.5 ± 3.9 |
| Waist Circumference (cm) | 98 ± 11 |
| Fasting glucose (mg/dL) | 96 ± 10 |
| Haemoglobin (mg/dL) | 13.9 ± 1.5 |
| HOMA index | 3.1 ± 2.4 |
| Total cholesterol (mg/dL) | 161 ± 36 |
| HDL cholesterol (mg/dL) | 48 ± 11 |
| Triglycerides (mg/dL) | 98 ± 41 |
| Serum albumin (g/dL) | 4.4 ± 0.3 |
| Serum globulin (g/dL) | 3.1 ± 0.6 |
| Serum creatinine (mg/dL) | 0.8 ± 0.2 |
| AST (IU/L) | 48 (32-67) |
| ALT (IU/L) | 64 (34-80) |
| ALP (IU/L) | 90 ± 33 |
| GGT (IU/L) | 45 (29-63) |
| LDH (IU/L) | 184 ± 32 |
| Total Bilirubin (mg/dL) | 0.7 ± 0.3 |
| Direct Bilirubin (mg/dL) | 0.3 (0.2-0.4) |
| Platelet count (103/mm3) | 202 ± 54 |
| Ferritin (ng/mL) | 45 (34-77) |
| Positive ANA, n (%) | 2 (5.5%) |
| Positive AMA, n | 0 |
| Positive ASMA, n | 0 |
| Positive LKM-1, n | 0 |
Data expressed as means ± SD, or median (interquartile range), as appropriate; HOMA: Homeostasis model assessment; HDL: High-density lipoprotein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma glutam.yl transpeptidase; LDH: Lactate dehydrogenase; ANA: Antinuclear antibodies; AMA: Antimitochondrial antibodies; ASMA: Anti-smooth muscle antibody; LKM-1: Liver-kidney microsomal antigen.